Furthermore, high METTL3 and YAP activities restrict the reduction of cell proliferation on drug treatment in NSCLC, indicating the potential of METTL3 dysregulation in conferring drug resistance in BC [36]. The gene discussed is METTL3; the disease is non-small cell lung carcinoma.